- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
13th Annual
Phase I & IIa Clinical Trials
21 - 22 February 2012
|
Phase I & IIa Clinical Trials
Accelerating the journey to Proof of Concept
Main themes for Phase I & IIa Clinical Trials 2012:
- Senior-level strategic insights into early phase development over the next 5 years - including outsourcing and how biopharm and pharma will work together
- Discover how industry are practically including patients in their early phase trials to speed up early phase development
- Learn how pharmaceutical and biotech companies are working with CROs in Phase I & IIa development
- Find out how to achieve early Proof of Concept: Practically adapting the development process to
- Emerging markets: Real life experience of conducting Phase I & IIa studies
- Cardiac safety, liver safety, PKPD testing and translatability: Keep fully up-to-date on implementing innovative techniques
- Rare disease and orphan drugs: Industry case studies on conducting early phase trials
Don't miss out on key updates on biomarkers, patients in first in man / first in human studies, exploratory trials, clinical safety, clinical pharmacology and accelerating the journey to proof of concept.
Take advantage of the first early phase event of 2012 - latest updates on biomarkers, patients in first in man / first in human studies, exploratory trials, clinical safety, clinical pharmacology and accelerating the journey to proof of concept
What makes it unbeatable?
- 40 brand new industry speakers
- 32+ Phase I & IIa clinical trial industry case studies read more
- 55+ expert industry speakers read more
- THREE clearly focused streams read more
- 150+ attendees read more
- 12+ hours of networking read more
- Inspirational speaker - Paralympian Gold Medallist Giles Long, MBE read more
- Wine tasting event - back by popular demand for for 2012 read more
- Latest updates on biomarkers, patients in first in man / first in human studies, exploratory trials, clinical safety, clinical pharmacology and accelerating the journey to proof of concept
Event write up 2012
Missed the event?
"Graham Hughes reviews the 13th Annual Phase 1 and 2a Clinical Trials conference,
highlighting key presentations on proof of concept and venture capital initiatives . . ."
Read the full article by clicking here
Keynote Speakers
Senior level industry decision makers including perspectives from large pharma, biotech, venture capital and financial analysts.
Click here for a full list of expert speakers
Keynote Speakers
Greg Simon
Senior Vice President, Patient Engagement Group
Pfizer
|
Paul de Koning
Vice President, Head Global Clinical Pharmacology & Exploratory Development
Astellas Pharma Global Development
|
Steve Street
Vice President for Research, Head of Pfizer R&D Continuous Improvement
Pfizer
|
James Noble
CEO
Immunocore
|
Joseph DeGeorge
Vice President, Safety Assessment
Merck Research Laboratories
|
Tony Johnson
Vice President, Discovery Medicine Clinical Pharmacology
Bristol-Myers Squibb Research
|
Kate Bingham
Managing Partner
SV Life Sciences
|
Douglas Tsao, MPH
U.S. Specialty Pharmaceuticals & CROs
Barclays Capital Equity Research
|
Stephen Unger, CFA
Director / Senior Analyst, Equity Research - Life Science Tools & Diagnostics
Lazard Capital Markets
|
Neil V. Smith
Director Regulatory Affairs
Chorus, Lilly Research Laboratories, Eli Lilly and Company, USA
|
Event Sponsors
Exhibitors
Media Partners
Missed this event?
See what Steve Street had to say about this event.
Steve Street discussed the "Large Pharma perspective: What lies ahead for early phase drug development over the next 5 years?" on Day 1 of the conference. Steve Street is Vice President for Research, Head of Pfizer R&D Continuous Improvement at Pfizer.
Advisory Board: Phase I & IIa Clinical Trials 2012
Click here to read a note from the advisory board
- Clare Nott, Senior Clinical Project Manager
- Daren Austin, Head, Biopharm Clinical Pharmacology & Biometrics, GlaxoSmithKline
- David R. Jones, Expert Pharmaco-Toxicologist, MHRA
- James Dow, Director of Clinical Pharmacology & DMPK, Prosidion
- Mark Egerton, Managing Director, Quotient Bioresearch
- Sally Hughes, Senior Director, Clinical Pharmacology & Clinical Diagnostic Services, Eli Lilly
- Assem S. el Baghdady, Director, AlphaBeta Pharma
- Ian Wilding, President, Ian Wilding Associates
Brand new interactive sessions
Testimonials from Phase I 2011
"Programme packed with really hot topics. Event well attended by experts in the field"
"Excellent conference with great networking opportunities"
"Enjoyable mix of science and operations - big picture with areas of detail"
"Exciting cocktail of topics, all pointing at improving early phase clinical trials"
"Well organised, pleasant conference - I learned a lot about what other companies do"
Phase I & IIa / Early Phase key topics to be covered:
- Biomarkers
- Patients in first in man / first in human studies
- Exploratory trials
- Clincal safety
- Clinical Pharmacology
- Accelerating the journey to proof of concept
Who Should Attend?
Vice President, Senior Director, Director, Heads of Department, Manager:
- Early Clinical Development
- Early Phase Clinical
- Exploratory Development
- Clinical Safety
- Clinical Pharmacology
- Clincal Science
- Translational Science
- Clinical Operations
- Clinical Outsourcing
- Project Management
- Exploratory Medicine
Feeds | Like | Share    |
Latest Agenda
Download the latest agenda
Updated 14 Feb 2012
FREE Wine Tasting Evening
Join the discussions
Follow us
Buy one 2 day conference pass and get one free*
Brand new offer for 2012!
We want to make sure that you are able to attend this important industry event
*offer applicable to employees of pharmaceutical and biotech companies only
Brand new for 2012: Site Visit!
Visit the Clinical Trials Centre at St. Mary's Hospital, Imperial College Healthcare NHS Trust
Free to attend - limited space available so make sure you register and quote CQ4156D
Latest tweets
Dates and Venues
21 Feb 2012 - 22 Feb 2012
The Lancaster London
Event Sponsors
Exhibitors
